{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["206(5)"],"submitter":["Orozco RMQ"],"pubmed_abstract":["Bovine mastitis is a frequent infection in lactating cattle, causing great economic losses. <i>Staphylococcus aureus</i> represents the main etiological agent, which causes recurrent and persistent intramammary infections because conventional antibiotics are ineffective against it. Mastoparan-like peptides are multifunctional molecules with broad antimicrobial potential, constituting an attractive alternative. Nevertheless, their toxicity to host cells has hindered their therapeutic application. Previously, our group engineered three mastoparan-L analogs, namely mastoparan-MO, mastoparan-R1, and [I<sup>5</sup>, R<sup>8</sup>] MP, to improve cell selectivity and potential. Here, we were interested in comparing the antibacterial efficacy of mastoparan-L and its analogs against bovine mastiti"],"journal":["Journal of bacteriology"],"pagination":["e0007124"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11112992"],"repository":["biostudies-literature"],"pubmed_title":["Employment of mastoparan-like peptides to prevent &lt;i&gt;Staphylococcus aureus&lt;/i&gt; associated with bovine mastitis."],"pmcid":["PMC11112992"],"pubmed_authors":["Oshiro KGN","Almeida CV","de Souza CM","Orozco RMQ","Macedo MLR","Franco OL","Marin VN","Cardoso MH","Pinto IB","Buccini DF"],"additional_accession":[]},"is_claimable":false,"name":"Employment of mastoparan-like peptides to prevent &lt;i&gt;Staphylococcus aureus&lt;/i&gt; associated with bovine mastitis.","description":"Bovine mastitis is a frequent infection in lactating cattle, causing great economic losses. <i>Staphylococcus aureus</i> represents the main etiological agent, which causes recurrent and persistent intramammary infections because conventional antibiotics are ineffective against it. Mastoparan-like peptides are multifunctional molecules with broad antimicrobial potential, constituting an attractive alternative. Nevertheless, their toxicity to host cells has hindered their therapeutic application. Previously, our group engineered three mastoparan-L analogs, namely mastoparan-MO, mastoparan-R1, and [I<sup>5</sup>, R<sup>8</sup>] MP, to improve cell selectivity and potential. Here, we were interested in comparing the antibacterial efficacy of mastoparan-L and its analogs against bovine mastiti","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 May","modification":"2025-04-26T07:51:06.695Z","creation":"2025-04-06T12:29:59.193Z"},"accession":"S-EPMC11112992","cross_references":{"pubmed":["38629875"],"doi":["10.1128/jb.00071-24"]}}